Matricelf's Major Milestone: Completion of Safety Study for Human Trials

Matricelf Moves Towards First Human Trials

Matricelf Ltd. (TASE: MTLF), a pioneering firm in regenerative medicine, has achieved a significant milestone in its journey toward human clinical trials for its cutting-edge engineered tissue implants aimed at treating spinal cord injuries. On June 17, 2026, the company announced it successfully finalized its Good Laboratory Practice (GLP) safety study, surpassing all set endpoints without reporting any abnormal findings.

The comprehensive safety study spanned evaluations of key safety parameters, such as toxicology, tumorigenicity, and biodistribution across a monitored population of 248 animals over a period of up to 39 weeks post-implantation. Remarkably, the results indicate no treatment-related toxicities, no indications of tumor development, and no relocation of the implant to other organs or tissues. Such outcomes strongly reinforce the safety profile of Matricelf’s primary therapeutic program.

This GLP study was strategically designed as an Investigational New Drug (IND) enabling safety program, marking a pivotal advance in Matricelf's strategy as it prepares for its first-in-human clinical trials. The success of this study is a critical component of the forthcoming regulatory submissions, aligning with the company’s clinical development roadmap.

Gil Hakim, CEO of Matricelf, shared, "This achievement signifies a monumental step for our company, bringing us closer to submitting an application for our inaugural human clinical trial. The data gathered provide compelling validation for the safety profile of our technology, representing a key progression toward converting our personalized neural tissue implant into a viable clinical treatment option for spinal cord injury patients."

The innovative development from Matricelf features a personalized neural tissue implant crafted to assist patients dealing with paralysis resulting from spinal cord injuries. The intricate tech behind this treatment fuses patient-derived cells with biomaterials, resulting in an autologous engineered implant tailored distinctly to each individual patient.

While the firm has made substantial strides, it underscores that the initiation of clinical trials is contingent upon the successful completion of ongoing preclinical studies, the attainment of regulatory approvals, and securing the necessary financing.

This news highlights Matricelf's commitment to revolutionizing treatment options for spinal cord injuries and embodies hope for many who suffer from paralysis. The company's focus on personalized solutions may set a new standard in regenerative medicine, potentially altering the treatment landscape significantly. As the field progresses, all eyes will be on Matricelf to see how it navigates the upcoming clinical phases and delivers on its promise to improve patient outcomes in spinal cord injury cases.